Genetics are a risk factor for developing dementia due to Alzheimer’s disease and now several Alzheimer’s prevention trials are focused on individuals, who based on their age and genetic profile, are at high risk for developing the disease.
From novel biomarkers, to the potential use of the Zika virus as a tumor treatment, read our round-up of the biggest neuro-oncology news from the last year as we mark World Cancer Day.
A recent re-evaluation study reported that soluble APP-α and APP-β in CSF are strongly correlated with phosphorylated tau and are potentially useful biomarkers for earlier diagnosis of dementia disorders.
In his latest column, David Howett reviews a recent paper from Gunn-Moore et al. on the relationship between Alzheimer’s disease and Type 2 diabetes.
Read the third and final installment of our debate, which looks ahead at future research trends and the potential for personalized medicine.
Read the second installment of our Alzheimer’s genetics debate, with this part focusing on current research priorities, challenges and ethical concerns.
In the first installment of this debate, our experts discuss the contribution of genetics to Alzheimer’s risk, the differences between early- and late-onset disease, and how new technologies have advanced our understanding of this ever-expanding field.